JPMorgan Says Sagility Shares Could Rise 30.6%, Maintains Buy Rating
JPMorgan's latest note sets a ₹58 price target, which the report says implies 30.8% upside. The headline attributes a potential 31% gain to Sagility's Chirok Health acquisition.
JPMorgan said in its latest note on Thursday, October 22, that Sagility shares could gain 30.6%. The firm maintained its "buy" rating and a target price of ₹58 per share, representing 30.8% upside from current levels. JPMorgan said Sagility announced the…